🔎 Trials Near Me

Inici › Limfoma de Burkitt › Arkansas

Assaigs clínics de Limfoma de Burkitt a Arkansas

5 estudis de Limfoma de Burkitt busquen participants en centres de Arkansas.

Ciutats de Arkansas

Text oficial de l'estudi (anglès)

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

  • Arkansas Children's Hospital, Little Rock
ReclutantFase 2
366 Days – 46 Years · Tots els sexes · Actualitzat el 2 d’oct. 2026 · NCT06124157

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

  • Arkansas Children's Hospital, Little Rock
ReclutantFase 2
365 Days · Tots els sexes · Actualitzat el 25 de set. 2026 · NCT06317662

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

  • Arkansas Children's Hospital, Little Rock
ReclutantFase 2
Edats de 1 a 30 · Tots els sexes · Actualitzat el 1 de set. 2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • Arkansas Children's Hospital, Little Rock
ReclutantFase 3
365 Days – 25 Years · Tots els sexes · Actualitzat el 25 d’ag. 2026 · NCT03959085

A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received Blinatumomab

  • Arkansas Children's, Little Rock
  • Arkansas Children's Northwest, Springdale
ReclutantEstudi observacional
Edats de 1 a 23 · Tots els sexes · Actualitzat el 25 de febr. 2026 · NCT07422337

De ClinicalTrials.gov, dades recuperades el 5 d’oct. 2026. Cada estudi estableix els seus propis criteris d'elegibilitat; l'equip de l'estudi decideix qui hi pot participar.